Discover open access scientific publications

Search, annotate, share and cite publications

Publications in Oncology

P3.12-10 Immunogenomic Characteristics of SCLC and LCNEC Redefined Molecular Subgroups

Journal of Thoracic Oncology

English

P1.16-06 Expanded Efficacy and Safety Analysis of PACIFIC Based on a PD-L1 Cutpoint of 25%

Journal of Thoracic Oncology

English

P2.16-47 “Improved aBVA Method” and “Anterior VAB Method” Result in Analogous Survival Benefits During Right Upper Lobectomy

Journal of Thoracic Oncology

English

P2.16-46 Clinical Outcomes and Treatment Strategies of Sarcomatoid Carcinoma of the Lung

Journal of Thoracic Oncology

English

P3.01-55 SF2: A PCYT-2 Inhibitor Prototype Is Capable of Inducing Citotoxicity in NSCLC

Journal of Thoracic Oncology

English

Phase I-Ii Trial of Gemcitabine-Based First-Line Chemotherapies for Small Cell Lung Cancer in Elderly Patients With Performance Status 0-2: The G-Step Trial

Journal of Thoracic Oncology

English

P2.01-120 First Study to Evaluate the Efficacy of SB Oral Solution to Prevent Neutropenia and FN Induced by Platinum-Based Chemotherapy in Lung Cancer

Journal of Thoracic Oncology

English

P1.16-49 Treatment of NSCLC Patients With Clinical N1 Disease: Is There an Advantage to Neoadjuvant Therapy?

Journal of Thoracic Oncology

English

P3.01-54 a Historical Comparison of Patients With Advanced NSCLC Harboring Uncommon EGFR Mutations Before and After the Approval of Afatinib in Japan

Journal of Thoracic Oncology

English

P2.01-104 Plasma T-Cell-Derived Circulating DNA in Advanced NSCLC Is Not Correlated With TIL but Has a Potential of Prognostic Value

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications in Oncology

P3.12-10 Immunogenomic Characteristics of SCLC and LCNEC Redefined Molecular Subgroups

P1.16-06 Expanded Efficacy and Safety Analysis of PACIFIC Based on a PD-L1 Cutpoint of 25%

P2.16-47 “Improved aBVA Method” and “Anterior VAB Method” Result in Analogous Survival Benefits During Right Upper Lobectomy

P2.16-46 Clinical Outcomes and Treatment Strategies of Sarcomatoid Carcinoma of the Lung

P3.01-55 SF2: A PCYT-2 Inhibitor Prototype Is Capable of Inducing Citotoxicity in NSCLC

Phase I-Ii Trial of Gemcitabine-Based First-Line Chemotherapies for Small Cell Lung Cancer in Elderly Patients With Performance Status 0-2: The G-Step Trial

P2.01-120 First Study to Evaluate the Efficacy of SB Oral Solution to Prevent Neutropenia and FN Induced by Platinum-Based Chemotherapy in Lung Cancer

P1.16-49 Treatment of NSCLC Patients With Clinical N1 Disease: Is There an Advantage to Neoadjuvant Therapy?

P3.01-54 a Historical Comparison of Patients With Advanced NSCLC Harboring Uncommon EGFR Mutations Before and After the Approval of Afatinib in Japan

P2.01-104 Plasma T-Cell-Derived Circulating DNA in Advanced NSCLC Is Not Correlated With TIL but Has a Potential of Prognostic Value